ADIL stock forecast
Our latest prediction for Adial Pharmaceuticals, Inc.'s stock price was made on the Dec. 12, 2019 when the stock price was at 1.68$.
In the short term (2weeks), ADIL's stock price should underperform the market by -5.87%. During that period the price should oscillate between -14.52% and +14.59%.
In the medium term (3months), ADIL's stock price should underperform the market by -15.79%. During that period the price should oscillate between -44.18% and +34.43%.Get email alerts
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which is focused on the treatment of alcohol use disorder. Its lead product AD04, a selective serotonin-3 antagonist is in Phase 3 clinical trial. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.61$ per share.
The book value per share is -0.20$
Three months stock forecastDec. 12, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|